Forte Biosciences (NASDAQ:FBRX) Stock Price Expected to Rise, Chardan Capital Analyst Says

Forte Biosciences (NASDAQ:FBRX) had its price objective boosted by Chardan Capital from $3.00 to $64.00 in a research note released on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Forte Biosciences Trading Up 4.6 %

NASDAQ FBRX opened at $6.11 on Friday. The firm has a market capitalization of $8.92 million, a price-to-earnings ratio of -0.38 and a beta of 0.04. The firm’s 50 day simple moving average is $5.46 and its 200 day simple moving average is $2.37. Forte Biosciences has a 1 year low of $4.11 and a 1 year high of $21.25.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.